For Wednesday, January 25th
ILMN, ATTD, CBAI, UNDT, EGOC, NWMT
Our Stocks to Watch today include Illumina Inc. (NASDAQ: ILMN), Attitude Drinks Inc. (OTCBB: ATTD), Cord Blood America Inc. (OTCBB: CBAI), Universal Detection Technology (OTCBB: UNDT), Energy 1 Corp. (OTC: EGOC) and NewMarket Technology Inc. (OTC: NWMT).
STOCKS TO WATCH
ILLUMINA INCORPORATED (NASDAQ: ILMN)
"Up 42.88% in morning trading"
Detailed Quote: http://www.otcpicks.com/quotes/ILMN.php
Illumina is a leading developer, manufacturer, and marketer of life science tools and integrated systems for the analysis of genetic variation and function. We provide innovative sequencing and array-based solutions for genotyping, copy number variation analysis, methylation studies, gene expression profiling, and low-multiplex analysis of DNA, RNA and protein. We also provide tools and services that are fueling advances in consumer genomics and diagnostics. Our technology and products accelerate genetic analysis research and its application, paving the way for molecular medicine and ultimately transforming healthcare.
ILMN News:
January 25 - Illumina Board of Directors to Review Unsolicited Acquisition Proposal from Roche
Illumina Board of Directors to Review Unsolicited Acquisition Proposal from Roche
Illumina, Inc. (NASDAQ: ILMN), a leading developer, manufacturer, and marketer of life science tools and integrated systems for the analysis of genetic variation and function, tonight acknowledged the announcement by Roche (OTC: RHHBY) that Roche has made an unsolicited acquisition proposal and intends to commence a tender offer to acquire all of the outstanding shares of Illumina’s common stock for $44.50 per share in cash.
Consistent with its fiduciary duties and responsibilities, and in consultation with its financial and legal advisors, Illumina’s Board of Directors will thoroughly review Roche’s proposal and make a recommendation to stockholders in due course that the Board believes is in the best interests of Illumina stockholders. Illumina stockholders are advised to take no action at this time pending the Board’s recommendation.
Goldman, Sachs & Co. and Bank of America Merrill Lynch are acting as financial advisors and Dewey & LeBoeuf LLP is acting as legal counsel to Illumina.
ATTITUDE DRINKS INCORPORATED (OTCBB: ATTD)
"Up 69.44% in morning trading"
Detailed Quote: http://www.otcpicks.com/quotes/ATTD.php
Attitude Drinks Inc. is an innovative, beverage brand development company with a focus on functional milk, ready-to-drink beverages. Phase III® Recovery Drink is the company's first, functional milk drink exploiting recent scientific evidence of the benefits of milk and protein as an exercise recovery aid. The February 2010 launch of Phase III marks the first time a sports drink has been formulated from real milk.
ATTD News:
January 24 - Attitude Drinks Announces Authorization in Walgreens Stores Within State of Florida
Attitude Drinks (OTCBB: ATTD), an innovative brand beverage development company and creator of the Phase III® Recovery brand, today announced a sales agreement with Walgreens, of Deerfield, IL.
The brand will be distributed to Walgreens stores throughout the majority of the state. This represents over 800 stores within the chain. Walgreens, a company built around the concept of one stop shopping, has now increased their focus into the health & wellness arena. They are striving to become the first choice for "health & daily living" in promoting what they refer to as a "well experience."
Roy Warren, CEO of Attitude Drinks commented, "The introduction of Phase III® into the authorized Walgreens locations throughout the state of Florida is a great indicator of brand growth and reception within the beverage community. The selling of Phase III® into these Walgreens stores, a chain recognized as one of the strongest drug and convenience stores in the country, is exciting and flattering. We intend to support this fantastic new relationship in raising the sales to their fullest potential."
"We are excited about the authorization of Phase III® Recovery in the Florida Division of Walgreens. It is clear that Florida consumers are looking to purchase Phase III® and now that it is available in Walgreens--problem solved," commented Jack Shea, Executive Vice President of Sales for Attitude.
CORD BLOOD AMERICA INCORPORATED (OTCBB: CBAI)
"Up 24.26% in morning trading"
Detailed Quote: http://www.otcpicks.com/quotes/CBAI.php
Cord Blood America is the parent company of CorCell, which facilitates umbilical cord blood stem cell preservation for expectant parents and their children. Its mission is to be the most respected stem cell preservation company in the industry. Collected through a safe and non-invasive process, cord blood stem cells offer a powerful and potentially life-saving resource for treating a growing number of ailments, including cancer, leukemia, blood, and immune disorders.
CBAI News:
January 24 - Breakthrough Therapy Using Cord Blood Banking Driving Stem Cell Industry
Five Star Equities Provides Stock Research on Cord Blood America & Aastrom Biosciences
Given some positive trends, the stem cell market could be set to skyrocket this year. A recent report from Kalorama Information titled "Worldwide Markets for Transplantation, Cord Blood Banking and Drug Development," estimates that the market for stem cell technologies will rise to over $700 million this year and could reach over $1 billion. Five Star Equities examines the outlook for companies in the Biotechnology industry and provides equity research on Cord Blood America Inc. (OTCBB: CBAI) and Aastrom Biosciences Inc. (NASDAQ: ASTM). Access to the full company reports can be found at:
www.fivestarequities.com/CBAI
www.fivestarequities.com/ASTM
Kalorama finds that cell therapies are largely confined to a few conditions. Oncological conditions such as leukemia, multiple myeloma and non-Hodgkins lymphoma are some of the most popular areas of research, although certain non-cancerous diseases like aplastic anemia, immunodeficiency and lupus are also increasingly addressed with stem cells.
Kalorama finds that cord blood banking is a source of revenue growth in the stem cell market. U.S. researchers are currently undergoing a phase I safety study using a child's umbilical cord blood stem cells to try to restore hearing loss. "This study is exciting because it might offer a non-surgical option for some children with profound hearing loss," explains Dr. James Baumgartner, sponsor of the study and guest research collaborator at The University of Texas Health Science Center at Houston Medical School.
Five Star Equities releases regular market updates on the biotechnology industry so investors can stay ahead of the crowd and make the best investment decisions to maximize their returns. Take a few minutes to register with us free at www.fivestarequities.com and get exclusive access to our numerous stock reports and industry newsletters.
Stem cells from umbilical cords do not pose an ethical dilemma because the cells come from a source that would otherwise be discarded, Science Daily reports. Recent studies suggest that stem cells from umbilical cords have been converted into other types of cells, which may eventually lead to new treatment options for nervous system diseases. "This is the first time this has been done with non-embryonic stem cells," says James Hickman, a University of Central Florida bioengineer and leader of the research group.
UNIVERSAL DETECTION TECHNOLOGY (OTCBB: UNDT)
"Up 100.00% in morning trading"
Detailed Quote: http://www.otcpicks.com/quotes/UNDT.php
Universal Detection Technology is a developer of monitoring technologies, including bioterrorism detection devices. The company on its own and with development partners is positioned to capitalize on opportunities related to Homeland Security. For example, the company, in cooperation with NASA, has developed a bacterial spore detector that detects certain biohazard substances. The company is also a reseller of handheld assays used for detection of five bioterrorism agents, radiation detection systems, and antimicrobial products.
UNDT News:
December 15 - Universal Detection Technology Announces Sale of Biological Weapon Detection Devices to US Army
Handheld Assays Detect the Presence of Biological Hazards Including Anthrax and Ricin
Universal Detection Technology (OTCBB: UNDT), a developer of early-warning monitoring technologies that protect against biological, chemical, and radiological threats, announced today that that it has received a purchase order from the US Army for its biological detection equipment.
A report released by the WMD Center released in October found that the United States is unprepared for a large-scale biological attack, despite spending more than $65 billion on biodefense over the past decade. The report warned that the threat of biological weapons is now greater than ever as a result of technological advances: "A small team of individuals with training in key disciplines can produce the type of bioweapons created by nation-states in the 1960s."
"We are very pleased to supply our armed forces with the tools to detect agents of Bioterror such as Anthrax and Ricin," said Mr. Jacques Tizabi, UNDT's Chairman and CEO. "We understand that, unfortunately, the threat posed by Biological weapons is very dangerous to the government and the civilian sectors," he added.
ENERGY 1 CORPORATION (OTC: EGOC)
"Up 16.67% in morning trading"
Detailed Quote: http://www.otcpicks.com/quotes/EGOC.php
Energy 1 Corporation is a U.S.-based Energy Research and Development Corporation, which is developing energy and emission solutions for the post carbon economy for the transportation industry.
EGOC News:
January 24 - Energy 1 Corporation Provides Status Update on Mid-East Project
Energy 1 Corporation (OTC: EGOC) announces that product engineering for integration on the Mercedes 0-457 diesel powered transit bus is near complete and anticipates Phase II of – in use – product demonstration & end-user testing to begin within 4 to 6 weeks from today.
"Phase II is the final phase of this demonstration & end-user testing protocol for product readiness within the middle-east market," said Raymond T. Brown, Chairman of E1. "We are on schedule and on target. With this last hurdle behind us, we'll be ready to start manufacturing pre-configured units for resale into the retrofit market for emission reduction on transit buses within the region; and while increased fuel efficiencies may not be as critical to customers in this area of the world verses Europe, the US & the Asian-Pacific markets, the fact that we include it answers any additional ROI calculations the consumer might have as part of their buying decision."
NEWMARKET TECHNOLOGY INCORPORATED (OTC: NWMT)
"Up 100.00% in morning trading"
Detailed Quote: http://www.otcpicks.com/quotes/NWMT.php
NewMarket's current portfolio of operating subsidiaries provides systems integration and technology infrastructure services. NewMarket's operations strategically focus on providing technology and support services in emerging and developing economies with high growth rate potential. NewMarket has operating subsidiaries today in China, Singapore, Brazil and Northern Latin America.
NWMT News:
October 27 - China Crescent Enterprises, Inc. Anticipates Potential Business Strategy Updates in Light of Recent NewMarket Technology, Inc. Announcement
China Crescent Enterprises, Inc. ("China Crescent" or the "Company") (OTC: CCTR) announced that it anticipates potential business strategy updates in light of a recent NewMarket Technology, Inc. ("NewMarket") (OTC: NWMT) announcement on October 20, 2011. China Crescent is a majority-owned subsidiary of NewMarket.
On October 20, NewMarket announced that it is exploring new potential investment relationships and an associated change of control event. China Crescent anticipates that any such investment relationship or change of control event of NewMarket would also impact the Company and its business strategy. The entire announcement is available on NewMarket's website.
On October 21, 2011, NewMarket also released a Current Report on Form 8-K to report that it received shareholder approval for an amendment to NewMarket's Articles of Incorporation to increase the number of its authorized shares of common stock. The amendment is solely for the purpose of increasing the number of authorized shares of common stock for NewMarket and specifically does not include a reverse split of its issued and outstanding shares. The 8-K can be reviewed in its entirety at:
China Crescent has no plans at this time to either increase the number of its authorized shares of common stock or reverse split its issued and outstanding shares.
|
